107 results on '"Kyrtsonis, Marie‐Christine"'
Search Results
2. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
3. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial
4. The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes
5. Primary therapy of Waldenström macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)
6. Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia
7. Prognostication of the High-Risk WM Patient
8. CD138 Expression Helps Distinguishing Waldenström's Macroglobulinemia (WM) From Splenic Marginal Zone Lymphoma (SMZL)
9. Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center
10. Clinical Characteristics and Outcome of Primary Systemic Light-Chain Amyloidosis in Greece
11. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH)
12. Staging Systems and Prognostic Factors as a Guide to Therapeutic Decisions in Multiple Myeloma
13. Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group
14. Soluble CD163; A Possible New Biomarker in Multiple Myeloma
15. Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World ‘Powerful’ Study
16. P-192 Increased serum CRBN levels are associated with improved survival in MM patients
17. Prognostic Value of Serum β2-Microglobulin in Patients with Waldenström's Macroglobulinemia Requiring Treatment
18. Development and validation of a clinical prediction rule for bone marrow involvement in patients with Hodgkin lymphoma
19. The Prognostic Significance of Serum Beta-2 Microglobulin (sβ2m) Levels in Patients with Hodgkin Lymphoma (HL): Final Analysis on 915 Patients Treated with ABVD or Equivalent (ABVDeq) Chemotherapy or Combined Modality Therapy (CT/CMT) Focusing to the Determination of Optimal Cut-Offs
20. P-174: Validation of Mayo Clinic 2018 and IMWG 2020 prognostic risk score for smoldering multiple myeloma (SMM), real world data; single center experience
21. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance
22. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders
23. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years
24. A Study of Ribonucleotide Reductase mRNA Expression and Its Prognostic Role in Patients with Chronic Lymphocytic Leukemia
25. Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study
26. Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study
27. P-085: Updated outcomes on Lenalidomide (Len) refractory MM patients’
28. Endogenous Interleukin 6 Conveys Resistance to cis-Diamminedichloroplatinum-Mediated Apoptosis of the K562 Human Leukemic Cell Line
29. Continuous Clinical Remisssion with High MRD Negativity and High PB and BM MRD Concordance during Venetoclax Monotherapy in R/R CLL Patients
30. Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study
31. Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study
32. Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients
33. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study
34. Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece
35. Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)
36. Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)
37. Real-world Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma in the Novel Therapeutic Era: A study of the Greco-Israeli Collaborative Myeloma Working Group
38. Uninvolved Immunoglobulin Suppression Determined By “Hevylite” ASSAY. Strongly Predicts Evolution of Smoldering Myeloma (SMM) to Symptomatic Multiple Myeloma (MM)
39. Increased SERUM VON Willebrand Levels in Chronic Lymphocytic Leukemia (CLL) Patients Are Related to a Shorter Time to Treatment
40. Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry
41. Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group
42. Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group
43. Bone Marrow Levels of PARP1 mRNA Predict Response to Treatment with 5-Azacytidine in Patients with Myelodysplastic Syndrome
44. A Revised Staging System for Waldenström's Macroglobulinemia
45. Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
46. Validation of Frailty Assessment in Multiple Myeloma (MM) Patients
47. Real-World data for the Treatment of Relapsed/Refractory Multiple Myeloma with Lenalidomide and Dexamethasone in 2nd Line (Legend Study): The Prognostic Significance of Biochemical Versus Clinical Relapse
48. Real-World Data on Clinical Characteristics, Prognosis and Outcome of Primary Plasma Cell Leukemia: A Study of the Greek Myeloma Study Group in the Era of Novel Agents
49. Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
50. Bortezomib, Dexamethasone and Rituximab in Newly Diagnosed Patients with WaldenströM’s Macroglobulinemia: Final Analysis of a Phase 2 Study after a Minimum Follow up of 6 Years
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.